Dr. Susheel K. Sharma

SUSHEEL K SHARMA
MBBS, MD (India), MRCP (UK), FACC (USA)

S-VYASA Deemed To Be University
Bengaluru

Phone: +91-98805 98017 

drsharma@blockagereversal.com 

CURRENT MISSION 

Program Director- Integrated Cardiac Rehabilitation & Research Center

Situated in Bengaluru at S-VYASA Deemed To Be University. This is India's first center for integrative cardiology. The Integrative Cardiology program reverses coronary artery disease by combining the transformational wisdom of yoga with aggressive lifestyle modification and state-of-the-art modern medical concepts.

• I was the former president of Maryland Heart Associates and an interventional cardiologist with board certification. From 1993 until 2022, I worked as an interventionist cardiologist in Maryland, where I was connected to the University of Maryland Baltimore Washington Medical Center. In addition to being a member of the American Society of Preventive Cardiology (ASPC), I am also a Fellow Emeritus of the American College of Cardiology (FACC), a Member of the Royal College of Physicians (MRCP UK), and a Member of the Physician Committee for Responsible Medicine (PCRM).

• In England, I received my general cardiology training at Manchester University and Leeds University. Furthermore, I finished my training for an Interventional Cardiology Fellowship at the Henry Ford Heart and Vascular Institute in Detroit, Michigan. In 2016, I changed my focus to Integrative Wellness after 25 years of working as an interventional cardiologist.

• My belief in the advantages of integrative wellness has been strengthened by reading through scientific research, reflecting on my own health transformation, and hearing from Integrative Wellness Science & Practice participants about their improvements in health. In my opinion, the integration of contemporary science with traditional Indian knowledge offers a solid basis for an integrated way of living that can be used to prevent, manage, and even reverse lifestyle illnesses.  

• The preceding online version since its inception has benefited thousands of participants worldwide by  applying principles of Integrative Wellness for lifestyle transformation. Hundreds of participants have also  participated in self-directed online 12-module programs. In addition, several hundred participants have  continued to follow our weekly connect segment of the Integrative Wellness Science and Practice program.

MEDICAL LICENSE  

• Maryland State Medical License 1993-current 

• Uttarakhand State Medical License-Since Jan 2023-current 

ACTIVITIES AND HONORS 

• Fellow American College of Cardiology 

• Member American Society of Preventive Cardiology 

• Member Physician Committee for Responsible Medicine 

CERTIFICATIONS

• Board Certified, Cardiovascular Medicine- 1991- Current 

EXPERIENCE

• ALL INDIA INSTITUTE OF MEDICAL SCIENCES, RISHIKESH, UTTARAKHAND

  • GUEST FACULTY DEPT OF CARDIOLOGY OCT 2023-PRESENT. 

• MARYLAND HEART ASSOCIATES, LLC, Glen Burnie, MD 

  • Founder/Managing Partner 07/2007 to April 2022

  • Established, developed organizational vision, mission, and foundational structure to create and facilitate the growth of Maryland Heart Associates. 

  • Oversaw strategic business decision-making to develop, enhance and enforce business mission.

  • Negotiated key initial contracts and established plans to formalize structure and support growth.

• UNIVERSITY OF MARYLAND - BALTIMORE WASHINGTON MEDICAL CENTER, Glen Burnie, Maryland 

  • Cardiology Consultant. 01/1994 – April/2022 Worked as a consultant Cardiologist since 1993. 

• DIRECTOR, CARDIAC CATHETERIZATION LAB, UNIVERSITY OF MARYLAND BALTIMORE WASHINGTON MEDICAL CENTER 

  • I was instrumental in starting and promoting the Primary Angioplasty Program for Acute Myocardial Infarction, as part  of the C_PORT Trial in 1999, at Baltimore Washington Medical Center. 

  • Developed and supervised staff by providing orientation, training, support, and direction for starting the Angioplasty Program

• MEDSTAR HARBOR HOSPITAL CENTER, Baltimore, Maryland

  • Chief, Division of Cardiology 07/2015 to 01/2018 • Planned and executed re-establishment of diagnostic Cardiac Catheterization Lab. 

  • Established and enforced policies and procedures to achieve goals and objectives. 

  • Provided oversight by monitoring organizational effectiveness and efficiency. 

• MEDSTAR UNION MEMORIAL HOSPITAL, Baltimore, Maryland

  • Associate Director, Cardiac Cath Lab. 07/2004 to 12/2015 Assisted the Director of the Catheterization Laboratory in implementing Policies and protocols. Participated in various trials of new interventional technologies 

• UNIVERSITY OF MARYLAND MEDICAL CENTER, UNIVERSITY OF MARYLAND Baltimore, Maryland 

  • Clinical Assistant Professor of Cardiology 1999-2022 

  • Attending, Cardiac Catheterization Laboratory 12/1994 to 07/2014 • Worked as an Interventional Cardiologist and performed diagnostic and interventional cardiac catheterization  laboratory procedures. 

  • Was actively involved in training Cardiology Fellows in performing Cardiac Catheterization and Angioplasty  procedures, under the guidance of the Cardiac Catheterization Laboratory Director. 

• ALVIN C. YORK VA MEDICAL CENTER, Murfreesboro, Tennessee

  • Chief, Division of Cardiology 10/1991 to 12/1993 Developed and directed a strong Cardiology Program at the hospital. I started new Cardiology programs including  Transesophageal Echocardiography and permanent Pacemaker Implantation.

  • Led and formalized regular Cardiology teaching programs for Interns, residents and medical students.

MEDICAL TRAINING  

Interventional Cardiology Fellowship. 

• July 1989- Nov 1991. 

• Henry Ford Heart and Vascular Institute, Detroit, MI. 

Cardiology Fellowship. 

• July 1988- June 1989. 

• Manchester University 

• Manchester Royal Hospital, Manchester England. 

Research Cardiology Fellowship 

• April 1985- June 1988. 

• Leeds University. 

• Leeds General Infirmary, Leeds, England. 

Internal Medicine Residency 

• July 1984- April 1985. 

• Tameside general Hospital, Lancashire, England 

Internal Medicine Residency 

• July 1983- June 1984 

• New Cross Hospital 

• Wolverhampton, 

EDUCATION AND TRAINING 

• M.B.B.S: MEDICAL DEGREE 05/1977 S.N. Medical College, Agra, India 

  • Dr. P.N. Wahi Gold Medal Recipient for outstanding performance in University Pathology Examination.

  • Ranked in Top 1% of the class.

• M.D: INTERNAL MEDICINE 07/1982 S. N. Medical College, Agra, India, India 

  • University Gold Medal Recipient. 

• M.R.C.P.C(UK) 05/1984 Royal College of Physicians, Glasgow, Scotland. 

ACTIVITIES AND HONORS 

• Fellow American College of Cardiology 

• Member American Society of Preventive Cardiology 

• Member Physician Committee for Responsible Medicine

• Member Royal College of Physicians  ( United Kingdom)

• Member European Association of Preventive Cardiology

RESEARCH STUDY PARTICIPATION

1. Principal-Investigator - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the  Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular  Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or  Multiple Cardiovascular Risk Factors (CAMELLIA), Eisai, Co, 2014-2017 

2. Principal-Investigator - Phase 3 Multicenter, Double-blind, Randomized, placebo-controlled, Parallel-Group  Evaluation of The Efficacy, Safety, And Tolerability of Bococizumab (PF04950615), In Reducing The Occurrence Of  Major Cardiovascular Events In High-Risk Subjects (SPIRE 1 & SPIRE 2), Pfizer, Inc, 2015-2016. 

3. Principal-Investigator - A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the  Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients  with Type 2 

Diabetes Mellitus (THEMIS), AstraZeneca, 2014-2017 

4. Sub-Investigator - A Clinical Evaluation of Absorb™ BVS, the Everolimus-Eluting Bioresorbable Vascular Scaffold 

in the Treatment of Subjects with de novo Native Coronary Artery Lesions (ABSORB RCT), Abbott Vascular, 2013- 2014. 

5. Sub-Investigator - A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous  canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (CANTOS), Novartis, 2012-2014 

6. Sub-Investigator - A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY TM  Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY TM Stent System) for the Treatment of  Atherosclerotic Lesion(s) (EVOLVE II), Boston Scientific, 2012-2014. 

7. Sub-Investigator - Evaluation of XIENCE PRIME ™ or XIENCE V versus Coronary Artery Bypass Surgery for  Effectiveness of Left Main Revascularization (EXCEL), Abbott Vascular, May 2012 – 2014. 

8. Sub-Investigator - A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent  System (PROMUS Element™) for the Treatment of up to two De Novo Coronary Artery Lesions (PLATINUM),  Boston Scientific, 2009-2014 

9. Sub-Investigator - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on  Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneously  Coronary Intervention with Incomplete Revascularization (RIVER-PCI), May 2012 – 2015. 

10. Sub-Investigator - A Prospective, Single-Blind, Randomized Controlled Study to Evaluate the Safety and  Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side  Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions  Involving the Main Branch and Side Branch within the Native Coronary Circulation. (TRYTON), Tryton Medical, Inc  2011-2014. 

11. Sub-Investigator -0020A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary  Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of  2.25mm to 4.2mm. (RESOLUTE US), Medtronic, 2008-2015 

12. Sub-Investigator - XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study.  (XIENCE V), Abbott Vascular, 2008-2013. 

13. Sub-Investigator - A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety  of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare-metal stent (BMS) placement for the treatment of coronary artery  lesions. (The DAPT Study), HCRI, 2010-2014. 

14. Sub-Investigator - A U.S. Post-Approval Study of the ION ™ Paclitaxel-Eluting Platinum Chromium Coronary  Stent System. (ION), Boston Scientific, 2011-2015. 

15. Sub-Investigator - A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System  for the Treatment of a Single De Novo Coronary Artery Lesion. (OMEGA), Boston Scientific, 2011-2014 

16. Sub-Investigator - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the  TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions (TAXUS PERSEUS), Boston Scientific, 2007-2014 

INVITED SPEAKER ENGAGEMENTS

• Integrative Wellness Science and Practice. April 17, 2023, SGT university, Gurugram, Haryana.

• How to reverse Lifestyle Disorders? April 15,2023. IMA Saharanpur Chapter. Saharanpur

• Reversal of CAD. March6,2023. World NCD Federation. 8th Foundation Day International CME. PGI Chandigarh.

• Yoga for Wellness. February3, 2023 .75 Lakh Surya namaskar Campaign celebration, Ministry of Aayush and health. Haryana State Government, Ambala.

• Early triage of acute MI patients for PCI. Guest Lecture. Jan 11, 2023.AIIMS Rishikesh

• Coronary Disease Reversal- Fact or Fiction. Jan 2, 2023, AIIMS, New Delhi

• Integrative Wellness Science and Practice Seminar. Oct 2, 2023, AIIMS Rishikesh

• Yoga and Hypertension. Guest Lecture Sept 10, 2022.BP CON ( National Meeting). Indian Society of Hypertension.

• Integrative wellness Science and Practice- June 19, 2022, International Yoga Day Celebration. Sanskrit University, Haridwar.

• Integrative wellness for preventing lifestyle disorders- May 2022, Sanskriti University. Haridwar.

• Integrative Wellness Science and Practice- April 2022. Dev Sanskriti University, Haridwar.

• Yoga and Wellness- June 2021, American Association of Yoga and Meditation (AAYM). USA.

• Integrative wellness for lifestyle disorders- March 2020, Max Hospital, Dehradun.

• Integrative Wellness Science and practice- March 2020, Ramakrishna Sevashram and Hospital, Kankhal India

• Wellness- Spanish Church June 2017. Glen Burnie Maryland

• Heart Health and Wellbeing- March 2015, Moose Lodge Maryland.
  Whole Food Plant Based Diet- June 2015, Vedanta Center Washington DC

PUBLICATIONS

1. Sharma SK, Tetter Ken, Khaja F; Role of coronary angioplasty in acute myocardial infarction. Henry Ford Hospital  Medical Journal. 1991; vol 3&4: 236-239. 

2. Silke B, Verma SP, Sharma SK, Baig W, Reynolds G, Grais MA, Jackson NC, Taylor SH: Hemodynamic dose response actions of cicloprolol in LV dysfunction due to ischemic heart disease. Int J Cardiol 1987; 17:127-136. 

3. Taylor SH, Lee PS, Sharma SK, A comparison of doxazosin and enalapril in the treatment of mild and moderate  hypertension. Am Heart J 1986 Dec 116 (6 PT2). 

4. Silke B, Verma SP, Sharma SK, Frais MA, Reynolds G, Taylor SH. Comparative effects of atenolol and cicloprolol  in cardiac performance in coronary heart ds. J Cardiovasc Pharm. 1989 Jan: 13 (1) 155-61. 

Abstracts: 

1. Sharma SK, Silke B, Verma SP, Reynolds G, Taylor SH. Hemodynamic dose-response effects of intravenous  diltiazem in coronary artery disease. Proc Xth World Congress of Cardiology, Washington, 1986; 2857A. 

2. Silke B, Sharma SK, Verma SP, Reynolds G, Midtbo K, Taylor SH: A hemodynamic and radionuclide assessment of  diltiazem in coronary artery disease. Br J Clin Pharmac 1987; 23:165-b172. 

3. Jackson N, Frais JMA, Sharma SK, Reynolds G, Taylor SH: A dose-response and hemodynamic study of  dopexamine vs. Dopamine in ischemic left ventricular failure. Proc Xth World Congress of Cardiology, Washington,  1986;2302A. 

4. Silke B, Verma SP, Reynolds G, Sharma SK, Taylor SH: A hemodynamic and radionuclide assessment of celiprolol  in coronary artery disease. Proc Xth World Congress of Cardiology, Washington, 1986;792A.